Genprex preclinical data shows Reqorsa overcoming resistance in lung cancer
Genprex (NASDAQ:GNPX), a clinical-stage gene therapy company, announced today that its collaborators presented compelling preclinical data for its lead drug candidate, Reqorsa® (quaratusugene ozeplasmid), at the American Association for Cancer Research (AACR) Annual Meeting 2026.










